Tabes Dorsalis

Earn CME/CE in your profession:


Continuing Education Activity

Tabes dorsalis, also known as locomotor ataxia, is a rare neurodegenerative disease caused by infection with Treponema pallidum subspecies pallidum, a bacterium responsible for sexually transmitted syphilis. The clinical manifestations of syphilis depend on the stage of the disease. Characterized by a slowly progressive degeneration of the dorsal columns and dorsal roots of the spinal cord, tabes dorsalis typically manifests decades after the initial infection. The disease presents with various symptoms, including sensory ataxia, lancinating pains, paresthesia, gastric crises, bladder dysfunction, and pupillary irregularities, most notably the Argyll-Robertson pupil.

Diagnosis relies on clinical suspicion and spinal fluid analysis. A reactive cerebral spinal fluid Venereal Disease Research Laboratory test confirms the diagnosis of neurosyphilis. However, a nonreactive result does not exclude the diagnosis, necessitating consideration of clinical manifestations, additional tests, and cerebrospinal fluid characteristics. Maintaining a high level of clinical suspicion is necessary. If left untreated, tabes dorsalis can cause Charcot spine and joints, dementia, blindness, and paralysis, among other serious complications. Treatment involves IV antibiotics, followed by prolonged monitoring to ensure successful eradication of the infection. 

This topic explores the clinical symptoms and progression of tabes dorsalis and the associated diagnostic challenges. Engaging in this endeavor will equip healthcare professionals with the necessary expertise and abilities to diagnose and treat tabes dorsalis promptly, thereby improving patient care and lessening the morbidity, mortality, and overall impact on the quality of life for individuals afflicted by this uncommon neurodegenerative condition.

Objectives:

  • Identify the clinical manifestations and neurological symptoms characteristic of tabes dorsalis.
    Differentiate between tabes dorsalis and other neurological conditions with similar presentations.
    Apply evidence-based guidelines for the treatment of tabes dorsalis, including the use of IV antibiotics.
    Collaborate with specialists, such as neurologists and infectious disease experts, to comprehensively manage tabes dorsalis.

  • Differentiate between tabes dorsalis and other neurological conditions with similar presentations.

  • Apply evidence-based guidelines for the treatment of tabes dorsalis.

  • Collaborate with other healthcare professionals to comprehensively manage tabes dorsalis.

Introduction

Tabes dorsalis, also known as locomotor ataxia, is a slowly progressive degenerative parenchymatous disease of the dorsal columns and dorsal roots caused by central nervous system (CNS) infection with Treponema pallidum subspecies pallidum.[1] Tabes dorsalis along with general paresis is considered tertiary or late neurosyphilis and distinguishes itself by exhibiting the lengthiest latent period among all forms of neurosyphilis, typically averaging around 20 years from primary infection to symptom onset, though occasionally early onset is reported.[1][2][3] While prevalent in the pre-antibiotic era, tabes dorsalis has become rare.

Clinically, patients often present with sensory ataxia and lancinating pains, characterized by sudden, intense stabbing sensations in the limbs, back, or face, which may persist for minutes to days. Less frequent symptoms include paresthesia and gastric crises, marked by recurrent bouts of severe epigastric pain, nausea, and vomiting, along with early-onset bladder dysfunction leading to urinary retention and overflow incontinence. Pupillary irregularities, notably the Argyll-Robertson pupil, are a characteristic feature associated with tabes dorsalis. Other neurological findings encompass absent lower extremity reflexes, impaired vibratory and positional sensation, deficits in touch, pain, and optic function. Chronic destructive changes in the large joints of the affected limbs may occur in advanced cases.

Neurosyphilis can present diagnostic challenges, and clinicians must maintain a high index of suspicion. Early recognition and appropriate treatment can lead to good clinical outcomes. 

Etiology

Treponemes are thin, spirally coiled helical spirochete bacteria. T pallidum subspecies pallidum, pertenue, and endemicum cause venereal syphilis, yaws, and endemic syphilis, respectively. T carateum causes pinta. Humans are the only natural hosts of T pallidum.  

Epidemiology

The true incidence of neurosyphilis, including tabes dorsalis, is challenging to ascertain despite increasing rates of primary and secondary syphilis worldwide. Recent data reveals that the number of cases of primary and secondary syphilis rose by 28.6% from 2020 to 2021. Current estimates reveal the prevalence of syphilis is 16.2 cases per 100,000.[4]

Nearly 75% of cases of primary and secondary syphilis occur in men between the ages of 25 and 34, likely due to the increasing number of cases in men who have sex with men (MSM).[5][6][5] Associated risk factors in MSM are methamphetamine use and having acquired recent sexual partners via social media.[7][8] A high rate of HIV co-infection exists in MSM who have syphilis. The incidence of HIV co-infection for MSM, men who have sex with women exclusively, and women are 45%, 7%, and 4%, respectively.[9][10][11] Since 2012, the incidence of syphilis in women has increased by 700%. Experts feel this increase is likely due to the rise in drug use. As a result of increasing cases in women, the number of cases of congenital syphilis is also increasing.

Globally, 25% to 35% of cases of syphilis progress to late neurosyphilis, with approximately one-third of these cases developing into tabes dorsalis. Experts suggest approximately 1.5% to 9% of patients with syphilis will develop tabes dorsalis.[12] In the United States, Black patients experience a significantly higher incidence of syphilis compared to their White counterparts.[6][13] Worldwide, the highest incidence of syphilis occurs in lower-income regions of Africa and Southeast Asia.[14]

Pathophysiology

Early Infection

T pallidum invades the body through direct contact with an infected lesion during sexual activity, by crossing the placenta, or rarely by blood transfusions and solid organ transplantation.[15][16] Infection may occur at any site of inoculation, including kissing or touching a person who has active lesions on the lips, mouth, breasts, or genitals.

Once the bacteria enters the host's body, it evades the immune system and causes the initial lesion or chancre. Concurrently, some organisms disseminate into regional lymph nodes.[15] Initially, the immune system infiltrates the chancre with polymorphonuclear leukocytes, later replaced by T lymphocytes. Studies reveal that fluids isolated from the lesions contain CD4+ and CD8+ T cells, activated monocytes, macrophages, and dendritic cells. The body also develops a humoral immune response, developing antibodies clinicians can detect early in the disease course. In essence, the immune system controls local disease while allowing the dissemination of spirochetes. This process permits the findings of secondary and tertiary syphilis if patients remain untreated.

Late Infection

Cellular immunity likely controls syphilis and plays a role in late syphilis. A prolonged latent period characterizes late syphilis, and researchers suggest waning immunity with aging or possibly a hypersensitive host with partial immunity reacting to treponemes as the underlying pathophysiology of late syphilis. Gummas, or late benign syphilis, are characterized pathologically by the presence of granulomas, supporting the idea of a cellular hypersensitivity reaction.

Neurosyphilis

Neurosyphilis occurs once T pallidum invades the CNS, which likely occurs soon after infection. CNS infection does not always result in a persistent infection. Some patients may clear the infection entirely, and some may clear the infection after a transient meningitis. Those who do not clear the infection completely are at risk for symptomatic neurosyphilis. 

The pathogenesis of tabes dorsalis involves an inflammatory response against the treponeme with perivascular infiltrates of lymphocytes, histiocytes, plasma cells, macrophages, T-helper cells, and the development of gummas or caseous necrosis in granulomata.

Cytokines released from these inflammatory cells cause additional cellular damage, promoting neuronal degradation. Direct treponemal invasion of large myelinated nerves may also lead to their degeneration and promote the development of neuropathy. Some studies demonstrate that T pallidum disrupts iron metabolism and homeostasis by forming reactive oxidative agents contributing to neuronal cellular damage.[17]

The net result of these processes is neurodegeneration with demyelination of the sensory nerve fibers in the dorsal roots and posterior columns of the spinal cord, ultimately resulting in the characteristic symptoms of ataxic gait and sharp, stabbing pain, often with paresthesias and other signs of nerve root compression.[18][19] Spinal cord atrophy may also occur and indicate a poorer prognosis.[18][20][21][22] Given the high rate of HIV coinfection with neurosyphilis in the United States, the clinical suspicion of neurosyphilis must always remain high in patients with HIV who develop neurological, visual, or otologic signs or symptoms.[11] 

Histopathology

Histologic examination reveals demyelination and subsequent degeneration of dorsal root neurons. The affected dorsal column appears pale white, stemming from the atrophy and corresponding pallor resulting from the loss of dorsal root axons and myelin sheaths.[20] 

Perivascular infiltration primarily comprises CD4+ and CD8+ T lymphocytes, macrophages, and plasma cells, accompanied by the obliteration of small vessels. Gummas, characterized by nodules of central caseous necrosis encircled by inflammation displaying a granulomatous appearance, may manifest throughout the central nervous system.[23][24] Although the infecting organisms are generally not visible in most cases of spinal cord lesions, their presence may still be detectable through 16S ribosomal deoxyribonucleic acid (rDNA) sequencing for T pallidum.[25][26][27]

History and Physical

Clinical suspicion is the key to diagnosing neurosyphilis. A previous history of a primary syphilitic lesion, the presence of ophthalmic or otological symptoms, or HIV infection can lead to clinical suspicion of syphilis. The stages of syphilis, based on clinical findings and timing, are not always clinically apparent.[15][28]

Stages of the Disease

The classification of syphilis divides it into early and late syphilis, with further delineation within these categories.

Early disease

  • Primary syphilis: Manifests as a single painless chancre at the site of inoculation and regional lymphadenopathy. The average time from infection to appearance of the chancre is 21 days, ranging from 3 to 90 days.
  • Secondary syphilis: Approximately 25% of patients will progress and present with a systemic illness within a few months, manifesting with a rash that may be diffuse or involve the palms and soles. Patients may also experience fever, malaise, pharyngitis, hepatitis, condyloma lata, and alopecia.
  • Early latent: Patients are asymptomatic, but serologic tests reveal infection. By definition, early latent infection occurs within 1 year of infection with T palladium. 

Late disease

Between 25% to 40% of untreated patients will develop late disease. Symptoms can manifest anywhere from 1 to 30 years following the initial infection. Affected patients may not have experienced symptomatic primary or secondary syphilis, making the diagnosis challenging.

  • Tertiary syphilis: Patients exhibit symptomatic manifestations involving the cardiovascular system or gummatous disease.[28]
  • Late latent syphilis: Serologic testing indicates infection, but the patient is asymptomatic. Late latent infection occurs more than 1 year following the initial infection.

Neurosyphilis

  • Early neurosyphilis: Many exposures resolve spontaneously in individuals with intact immune systems. Nearly 40% of patients experience asymptomatic neurological involvement.[3] Affected patients may present with asymptomatic meningitis, symptomatic meningitis, or, less commonly, meningovascular disease like a stroke. Some patients may present with vision or hearing loss without concomitant meningitis. In patients with HIV infection, the presence of photophobia, vision loss, or diminished hearing along with gait incoordination makes the likelihood of neurosyphilis higher.[3][29]
  • Late neurosyphilis: Most commonly presents as general paresis or tabes dorsalis. General paresis is a progressive dementing illness initially manifesting as forgetfulness and personality change, progressing to severe dementia. Symptoms generally develop 10 to 25 years following initial infection but may present as early as 2 years after infection. Less frequently, affected patients can present with depression, mania, or psychosis. Additional associated symptoms are dysarthria, hypotonia of the face and limbs, intention tremors of the face, tongue, and hands, and abnormal reflexes. Pupillary abnormalities may be present but are more likely associated with tabes dorsalis.[30][31][32][33] 

Presently, early neurosyphilis is more prevalent than its late counterpart and is especially common among individuals with concurrent HIV infection. Tabes dorsalis has an average latent period of 20 years between primary infection and the onset of symptoms, making having a high index of suspicion necessary.[1][3][30][31] Symptoms of tabes dorsalis include ongoing loss of pain sensation, peripheral reflexes, impairment of vibration and position senses, paresthesias, and progressive ataxia.[1][34][1] In addition, patients experience intermittent bouts of acute, severe stabbing pain, primarily in the back, abdomen, or legs.[1] The pain may only last a few minutes or persist for days.[1] The painful crisis may develop associated with cold exposure, stress, or without any identifiable stimulus. Visceral crises may result in recurrent attacks of severe epigastric pain due to gastric symptoms, along with nausea and vomiting. Urinary retention with overflow incontinence and impotence may occur in the early stages of the disease.

Physical Examination

Abnormalities of the pupil are a hallmark finding on physical examination in patients with tabes dorsalis. An Argyll-Robertson pupil accounts for nearly 50% of these abnormalities. An Argyll-Robertson pupil is small and irregular and does not constrict to light but constricts briskly to near targets. Its dilation response to mydriatics is imperfect and does not dilate in response to painful stimuli.[35] See StatPearls' companion topic, "Argyll Robertson Pupil" for more detailed information regarding the pathophysiology underlying an Argyll Robertson Pupil.

Other examination findings include decreased lower extremity deep tendon reflexes, diminished pain sensation, sensory ataxia, and a positive Romberg test with proprioceptive deficits affecting nearly 60% of patients.[10] The absence of normal proprioception leads to a distinct wide-based, purposeful, unsteady gait, where the patient's feet "slap" or "stomp" the ground. These findings indicate severe dorsal column dysfunction or peripheral nerve disease. Patients can mitigate this effect by watching their feet while walking. Deficiencies in vibrational and tactile sensation may also be evident. Additionally, manifestations such as optic atrophy and progressive joint degeneration may be observed.[10] Late stages demonstrate severe spastic paraparesis and autonomic neurogenic dysfunction.[36] 

Charcot joints, most commonly affecting the knees and hips, may also be present.[37] Charcot spine, or spinal neuroarthropathy, characterizes the rare but progressive deterioration of bone, cartilage, intervertebral discs, and ligaments in the spine due to prolonged sensory loss and lack of proprioception.[38] Historically associated mainly with tabes dorsalis, it has more recently been linked to spinal cord injuries accompanied by sensory and proprioceptive deficits.[39][38][40][41] Common symptoms and signs include vertebral destruction, pain, paresthesias, weakness, decreased sensation, spasticity, diminished deep tendon reflexes, autonomic dysfunction, and spinal instability leading to deformity, typically kyphosis.[25][39][42][43][44][45][46][47]

Sensory loss disrupts normal protective muscle contractions, resulting in recurrent spinal microtrauma and localized inflammatory effusions. Traumatic microfractures contribute to bone and cartilage fragments to the effusions, exacerbating inflammation, forming calluses, narrowing intervertebral disc spaces, damaging ligaments, and possibly leading to paraspinal masses.[25][39][38][42][43][48] Progression may result in compression fractures, vertebral destruction, kyphosis, or nerve root compression with associated neurological symptoms.[39][43][44][45][46] 

Evaluation

Establishing the diagnosis of tabes dorsalis can present diagnostic challenges. Clinicians must consider the clinical presentation, examination findings, laboratory data, history of concurrent HIV infection, and possibly imaging studies.[3] Since T pallidum cannot be grown in a culture medium, serology and CSF examinations are the mainstays of laboratory evaluation of late-stage syphilis. and can reasonably confirm the diagnosis of late neurosyphilis.[3][15][49][50] 

Sensory evoked potentials from the tibial nerve may be delayed depending on pathological involvement of the dorsal roots, but nerve conduction testing is typically normal since motor neurological activity is unaffected.[51]

Serological Testing  

Serologic tests aid in providing a presumptive diagnosis of syphilis. Categorized into nontreponemal and treponemal-specific tests, relying solely on 1 test is inadequate due to the potential for false-positive results, particularly with nontreponemal tests. False-negative results can also occur, particularly in patients with advanced immunosuppression or during early disease stages, as serologic testing depends on a humoral immune response. 

Nontreponemal assays

Nontreponemal assays detect antibodies against lipoidal antigens and are semi-quantitative. The amount of antibodies present generally reflects the infection's activity; over time, they tend to become nonreactive and are also used to indicate a response to treatment. Labs report positive nontreponemal tests as a titer of antibody. For example, a titer of 1:32 represents the detection of antibodies in serum diluted 32-fold. Nontreponemal tests can be run on blood, serum, or cerebrospinal fluid (CSF) and include:

  • Rapid plasma reagin (RPR);
  • Venereal Disease Research Laboratory (VDRL); and 
  • Toluidine Red Unheated Serum Test (TRUST).[52]

Treponemal antibody tests

Treponemal tests detect antibodies against antibodies directed against specific treponemal antigens and are more specific than nontreponemal assays. Treponemal tests are qualitative and only reported as reactive or nonreactive. Most infected patients remain positive for life, and these tests are not helpful for disease tracking. Some patients can become negative in 2 to 3 years if treated early during the primary syphilis stage. Treponemal assays are:

  • Fluorescent treponemal antibody absorption (FTA-ABS)
  • Microhemagglutination test for antibodies to T pallidum (MHA-TP)
  • T pallidum particle agglutination assay (TPPA)
  • T pallidum enzyme immunoassay (TP-EIA)
  • Chemiluminescence immunoassay (CIA)

Serologic testing should involve both nontreponemal and treponemal tests. Confirmatory testing is necessary due to the potential for false-positive results. CSF evaluation is necessary when neurosyphilis is suspected. Interpretation of serologic testing depends on clinical disease presence, prior syphilis history, and the individual's immune status. Clinicians confirm a new syphilis infection with a positive nontreponemal and treponemal test in those without prior syphilis.

In patients with a history of treated syphilis, a positive nontreponemal test may indicate a new infection, treatment response, or treatment failure. Patients with a positive nontreponemal and negative treponemal test are usually considered false-positive. Those with recent high-risk exposures should undergo repeat testing. Causes of false-positive nontreponemal tests are pregnancy, acute infection, recent immunization, or autoimmune conditions. Conversely, a positive treponemal and negative nontreponemal test may indicate previously treated syphilis or early or late syphilis. Negative nontreponemal test results in patients with early syphilis symptoms may be false-negative due to testing timing or prozone effects, where antibody levels are high and interfere with clumping of antigen-antibody complexes. Latent syphilis is diagnosed in asymptomatic patients with serologic evidence of infection, classified as early latent if acquired within 12 months and late latent otherwise.

Patients with an Unknown Syphilis History

The first step in the diagnosis of neurosyphilis is confirmation of infection with T pallidum. Nontreponemal tests are typically positive in early neurosyphilis but may be nonreactive in late neurosyphilis. For this reason, treponemal antibody tests are necessary for patients with expected tabes dorsalis.

Patients with a Known History of Syphilis

A lumbar puncture is necessary in any patient with a known history of syphilis who presents with neurologic, otologic, or ocular symptoms. Clinicians should also consider a lumbar puncture in any patient with similar symptoms potentially caused by syphilis but who has an unknown syphilis history. The United States Centers for Disease Control (CDC) recommendations state that a patient with a known history of syphilis warrants a lumbar puncture to evaluate for the possibility of symptomatic or asymptomatic neurosyphilis if they exhibit neurologic or ophthalmic signs or symptoms in any stage of syphilis, evidence of active tertiary syphilis affecting other parts of the body, or treatment failure in any stage of syphilis.[3][53]

Some experts advocate for performing a lumbar puncture in all patients diagnosed with syphilis and concomitant HIV infection. Those with a CD4+ T cell count of 350 cells/µL or less, an RPR titer of ≥1:32, detectable plasma HIV ribonucleic acid, or those who are not receiving antiretroviral therapy are at notably higher risk of asymptomatic neurosyphilis. Historical data from the pre-antibiotic era demonstrates improved patient outcomes with the detection of asymptomatic neurosyphilis. However, there is a lack of data from the antibiotic era to address this concern directly. European guidelines recommend lumbar puncture for HIV-positive individuals with syphilis who exhibit the risks mentioned earlier since treatment with penicillin at higher doses for longer durations than used for primary and secondary syphilis may retard or prevent the development of clinically debilitating neurosyphilis later.[3][11] Also, symptoms associated with late neurosyphilis are less amenable to reversal.

Cerebrospinal Fluid Findings in Tabes Dorsalis

The CSF findings associated with neurosyphilis are:

  • Increased protein concentration of 45 to 75 mg/dL;
  • CSF pleocytosis >20 WBCs/µL;
  • Positive VDRL; and
  • TPHA titer >1:320.[54][55] 

A reactive CSF-VDRL confirms the diagnosis of neurosyphilis. A nonreactive result does not exclude the diagnosis.[3] A false-positive result can occur if the CSF is grossly bloody and the serum nontreponemal test titer is high. Recent studies reveal the CSF-VDRL has a sensitivity of 67% to 72%.[56][57] CSF RPR testing is generally not done due to its lower sensitivity, though VDRL is not available in some parts of the world, and RPR is necessary.[3]

Clinicians order a CSF FTA-ABS or CSF-TPPA if the CSF-VDRL is nonreactive. Although less specific than a CSF-VDRL, the CSF FTA-ABS or CSF TP-PA tests are more sensitive, and if negative, neurosyphilis is highly unlikely. For patients who have a lymphocytic CSF pleocytosis and a nonreactive CSF-VDRL, a nonreactive CSF FTA-ABS test excludes the diagnosis of asymptomatic neurosyphilis in most instances. Researchers have investigated nested polymerase chain reaction (nPCR) testing of the CSF in the diagnosis of neurosyphilis. One study reveals that nPCR has a sensitivity of 42.5% and a specificity of 97%.[58] 

CSF pleocytosis and raised CSF protein concentrations are consistent with neurosyphilis. A normal CSF white blood cell count and protein concentration would make a diagnosis of late neurosyphilis and tabes dorsalis highly unlikely.[25] A CSF pleocytosis and elevated protein concentration can be used to confirm the diagnosis in patients with a negative CSF-VDRL if no HIV infection is present, as HIV infection can cause pleocytosis and an elevation in CSF protein concentration.[59][60] Patients with HIV and taking antiretroviral agents who have CD4 counts ≤200 cells/µL or have an undetectable plasma HIV RNA viral load reduce the risk of pleocytosis caused by HIV by 70% to 96%. Neurosyphilis is more likely the cause of pleocytosis in these patients than HIV infection.

Recent studies demonstrate the role of testing levels of C-X-C motif chemokine ligand 13 (CXCL 13), a B cell chemokine, to help distinguish between CSF pleocytosis due to syphilis and CSF pleocytosis due to HIV. This test is not currently widely available. The value of CXCL 13 increases in HIV-infected patients accompanied by tabes dorsalis.[53]

Imaging 

Abnormal magnetic resonance imaging (MRI) findings associated with tabes dorsalis are only infrequently noted. Swelling and high signal intensity enhancement in the affected spinal cord segment after gadolinium administration, known as the "flip-flop" sign, and peripheral band-like enhancement suggest focal inflammation of the spinal cord compatible with tabes dorsalis.[20][49][60][61][62][63] Strong, intense longitudinal signaling along the dorsal spinal columns and spinal cord atrophy may also be additional findings, which indicate a poorer prognosis.[18][20][21][22] Diagnosing Charcot spine is challenging due to its rarity, nonspecific symptoms, and delayed onset long after initial infection. Clinical indicators include identifying spinal regions displaying neurological impairment and excessive mobility, particularly in the thoracolumbar and lumbosacral junctions. The lumbosacral spine is frequently affected, and symptoms may persist post-antibiotic treatment. While serological testing can confirm the diagnosis, initial symptoms are often nonspecific, potentially causing diagnostic delays.[25][39] MRI and computed tomography (CT) imaging help diagnose Charcot spine, especially if they reveal gas inside the disc space caused by a vacuum effect from excessive motion. This finding is highly suggestive of the diagnosis but is subtle and may be challenging to visualize.[39][64] 

Treatment / Management

According to the CDC, penicillin stands as the preferred treatment for all stages of neurosyphilis, including tabes dorsalis. Aqueous crystalline penicillin G is the formulation of choice for tabes dorsalis and late neurosyphilis. Clinicians treat ocular or otologic syphilis as neurosyphilis. Patients should undergo HIV screening before initiating treatment. The treatment regimen for neurosyphilis is aqueous penicillin G 3 to 4 million units intravenously (IV) every 4 hours or 18 to 24 million units continuous IV infusion daily for 10 to 14 days. Because the duration of this regimen for neurosyphilis is shorter than the regimens used for other forms of late syphilis, some experts recommend a one-time dose of 2.4 million units of benzathine penicillin G intramuscularly (IM) after completing IV therapy. Insufficient evidence exists to support this practice, and further studies are necessary.

Currently, no alternatives exist to IV therapy. Previously, procaine penicillin G 2.4 million U/d IM combined with probenecid 500 mg orally 4 times/d for 10 to 14 days was an acceptable option, but procaine penicillin is no longer available. 

The CSF-VDRL may be negative in as many as 70% of patients with neurosyphilis, making the diagnosis of neurosyphilis uncertain. Experts recommend treating with IV penicillin G if the patient has a compatible clinical syndrome, risk factors for syphilis, reactive blood serology for syphilis, and a CSF pleocytosis, even if the CSF-VDRL is not reactive.

If signs and symptoms persist in conjunction with clinical assessment of interval serologies and CSF testing, further courses of penicillin may be warranted. The chance of relapses is particularly high in patients with HIV. Treatment of early neurosyphilis arrests the disease and halts symptom progression, possibly preventing the development of tabes dorsalis. Symptom improvement may also occur. Treatment of late neurosyphilis and tabes dorsalis, however, may only limit disease progression without necessarily improving existing symptomatology.

Patients with Penicillin Allergy

Patients with a penicillin allergy should undergo skin testing for confirmation, as penicillin is the preferred antibiotic therapy.[65][66][67] Nearly 90% of patients with a reported penicillin allergy do not have a true allergy.[66][67][68] Patients with a penicillin allergy should undergo evaluation by an allergist to determine if they can be desensitized or rechallenged with penicillin.[67][68] 

If penicillin desensitization is impossible, the CDC recommends ceftriaxone 1 to 2 g/day IM or IV for 10 to 14 days.[69][70][71][72][73] Cross-reactivity between penicillin and ceftriaxone is possible but rare. Patients can undergo skin testing in select cases.[74] One study reports the successful use of ceftriaxone and dexamethasone as a good alternative after aqueous penicillin G treatment failure in a patient with tabes dorsalis.[60] Patients who are unable to be desensitized to penicillin and are unable to tolerate cephalosporins can use doxycycline 200 mg twice daily for 21 to 28 days. This regimen has limited clinical data supporting its use, and clinicians should reserve it for extreme cases. 

The Jarisch-Herxheimer reaction (JHR) is an acute, self-limiting febrile response that typically occurs within the first 24 hours following treatment for spirochetal infections like syphilis. Occurring in approximately 10% to 35% percent of cases, most commonly after treating early syphilis, the symptoms generally resolve within 12 to 24 hours, and patients can use nonsteroidal anti-inflammatory medications to help with the symptoms.[75] Symptoms include fever and systemic manifestations such as headache, myalgias, rigors, diaphoresis, hypotension, and worsening of rash. Rarely, it can lead to meningitis, respiratory distress, renal or hepatic dysfunction, mental status changes, stroke, seizures, and uterine contractions in pregnancy. The exact mechanism remains unclear, but accelerated phagocytosis by white blood cells, followed by the release of various inflammatory substances from killed organisms, is likely.[75] No preventative measures exist, and patients should be aware of this possible reaction. 

Additional treatments are symptomatic and depend upon the clinical signs and symptoms. Analgesics such as opiates and valproate may be helpful for severe pain crises. Physical or occupational therapy is helpful to prevent muscle wasting and weakness. Sexual partners must be fully educated about the condition and provided with preventive drug therapy.

Posttreatment Surveillance

Following treatment, patients should undergo a neurologic examination and lumbar puncture at 3 and 6 months, followed by repeat evaluations at 6-month intervals until the CSF white blood cell count is normal and the CSF-VDRL is nonreactive.[3] Successful treatment is marked by a decline in the CSF white blood cell count within 6 months, with complete resolution of all CSF abnormalities within 2 years after treatment. Retreatment is necessary if the patient experiences any increase in the CSF white blood cell count, a fourfold increase in CSF-VDRL titer, or the CSF white blood cell count does not decrease within 6 months, or all CSF abnormalities do not resolve within 2 years. CSF abnormalities may normalize slower in patients with HIV infection.

Charcot Spine 

Treatment for Charcot spine involves addressing individual symptoms, such as autonomic dysreflexia, and performing spinal fusion surgery to stabilize the spine and alleviate nerve root compression.[39][76][77][78] Surgical interventions for Charcot spine are complex and involve reconstructing, stabilizing, realigning, and fusing the spine.[79] Due to the spine's high mobility and weakened vertebrae, particularly in the lumbosacral region where shear forces are significant, nearly 75% of patients require at least one surgical revision to achieve a successful fusion.[79] Complications may necessitate additional surgeries in up to 40% of patients.[80] A recent surgical approach involving triple rod stabilization of the lumbosacral spine with tricortical laminovertebral screws has shown promise in 3 patients with extensive spinal neuroarthropathy, yielding good results without the need for revisions.[79] However, further research is needed to evaluate the long-term efficacy of this technique.

Those who are unable or opt not to undergo surgery utilize conservative measures like braces and bed rest.[39] Some researchers have suggested bisphosphonate therapy based on its use in managing Charcot foot neuropathy, although current studies yield conflicting results.[39][81][82][83][84]

Differential Diagnosis

Conditions affecting the spinal cord predominantly involving the dorsal columns share a similar presentation. A comprehensive evaluation is necessary to ensure accurate diagnosis and prompt initiation of treatment. The differential diagnoses include:

  • Hereditary and Other Demyelinating Disorders
    • Hereditary spastic paraplegia;
    • Amyotrophic lateral sclerosis;
    • Spinal muscular atrophy;
    • Friedreich ataxia; and
    • Adrenomyeloneuropathy.[85]
  • Miscellaneous Spinal Cord Myelopathy
    • Vitamin B-12 deficiency;
    • Copper deficiency;
    • Nitrous oxide and heroin intoxication;
    • Lathyrism, an incurable neurological disorder resulting from excessive consumption of grass pea, which clinically manifests as paralysis of lower limbs; and
    • Excessive zinc intake.[86][87]
  • Non-Syphilitic Argyll Robertson Pupil
    • An ophthalmological consult is recommended with pupillary abnormalities when diagnosing tabes dorsalis. Other diseases that may cause an Argyll Robertson pupil are diabetes and multiple sclerosis. Holmes-Adie syndrome, Lyme disease, and sarcoidosis may present with a tonic pupil and confound the proper diagnosis of tabes dorsalis.[35]
  • Additional Differential Diagnoses
    • Postinfectious demyelination; 
    • Vascular disease myelopathy due to diminished perfusion and infarction; and
    • Spinal tumor-induced myelopathy.[88][89][90]

Distinguishing features of hereditary and other demyelinating disorders are progressive neurodegeneration and demyelination along with muscle atrophy and weakness, ataxia, paraplegia, and sensory loss. In addition, their associations with diabetes, cerebellar disease, scoliosis, and the absence of primary and secondary syphilitic lesions, as well as nontreponemal and treponemal test results, help exclude tabes dorsalis. MRI of the brain and spinal cord is necessary to diagnose correctly.[85] 

Vitamin B12 deficiency leads to subacute combined degeneration of the dorsal and lateral columns of the spinal cord. When accompanied by megaloblastic anemia, the hemogram, and nontreponemal and treponemal tests help to differentiate it from tabes dorsalis. Copper deficiency myelopathy also involves the posterior column of the spinal cord resembling tabes dorsalis. Other toxins, such as nitrous oxide and heroin intoxication, produce posterior and lateral column myelopathy. MRI findings can assist in the exclusion of these myelopathies from tabes dorsalis.

Prognosis

The prognosis of tabes dorsalis is generally good after proper treatment, especially if diagnosed early, but if left untreated, can lead to paralysis, dementia, and blindness. Existing nerve damage cannot be reversed. 

Complications

General Complications of Syphilis 

  • Aortitis and aortic aneurysm
  • Dementia
  • Stroke
  • Membranous glomerulonephritis
  • Paroxysmal cold hemoglobinemia
  • Disfigurement by gummas
  • Hearing loss
  • Renal failure

Complications Associated with Tabes Dorsalis

  • Joint degeneration resulting in deformities or Charcot joints
  • Periarticular pathological fractures
  • Dementia
  • Paralysis
  • Blindness
  • Postural hypotension
  • Charcot spine

Deterrence and Patient Education

Syphilis, a sexually transmitted infection (STI), has seen an increase in incidence globally, prompting concerns of an epidemic.[28] However, with health initiatives, comprehensive sexual education, and easy access to affordable condoms and other protective measures, the incidence of syphilis can be better managed.

Healthcare professionals should focus on informing sexually active patients about the risks associated with unprotected intercourse. In addition, these efforts should familiarize individuals with the signs and symptoms of various STIs, aiming to reduce stigma and encourage seeking timely medical attention for both patients and their partners. Routine screening for syphilis during pregnancy is also a crucial public health measure.

The prognosis for syphilis including tabes dorsalis is good if diagnosed and treated early. When improperly treated or left untreated, it can lead to dementia, paralysis, blindness, and aortitis. Healthcare professionals must educate affected patients on the importance of completing the entire treatment course and attending follow-up appointments to ensure successful treatment. Encouraging individuals to seek medical help promptly if new symptoms arise is vital, particularly in regions where societal stigma may lead to reluctance to seek care.

Enhancing Healthcare Team Outcomes

Tabes dorsalis, also known as locomotor ataxia, is a rare neurodegenerative disease caused by T pallidum infection. Tabes dorsalis is a late manifestation of neurosyphilis characterized by a prolonged latent period averaging approximately 20 years. A disease of the posterior columns of the spinal cord and the dorsal roots, patients present with sensory ataxia, lancinating pains, paresthesia, gastric crises, and bladder dysfunction. Notably, pupillary irregularities such as the Argyll-Robertson pupil are common. 

Clinical suspicion and spinal fluid analysis are the keys to diagnosing neurosyphilis. A reactive CSF-VDRL establishes the diagnosis of neurosyphilis, but a nonreactive result does not exclude the diagnosis. Clinicians must consider the combination of clinical manifestations, treponemal and nontreponemal tests, and CSF characteristics. In addition, clinicians must take into consideration a patient's HIV status when making a diagnostic decision, as guidelines suggest a lower threshold for a lumbar puncture for patients with HIV, and HIV infections cause changes in the CSF similar to those associated with neurosyphilis. Treatment requires IV antibiotics and prolonged posttreatment monitoring to ensure successful infection eradication.

To enhance patient-centered care, outcomes, patient safety, and team performance related to tabes dorsalis, healthcare professionals must employ a multifaceted approach that emphasizes skills, strategy, interprofessional communication, and care coordination. Clinicians should thoroughly understand tabes dorsalis, its clinical presentation, and diagnostic challenges. Physicians, advance care practitioners, nurses, pharmacists, ophthalmologic clinicians, and all other healthcare professionals involved in the care of patients with tabes dorsalis must maintain open communication channels to share their expertise, discuss diagnostic strategies, and facilitate timely diagnosis and treatment. Effective care coordination is vital in enhancing outcomes and patient safety by empowering individuals to recognize symptoms, adhere to treatment regimens, and seek timely medical attention. Additionally, public health efforts aimed at increasing awareness, promoting sexual education, and facilitating routine screening for syphilis are essential to mitigate the incidence and impact of this potentially devastating disease.


Details

Updated:

3/7/2024 8:45:33 PM

References


[1]

Elmouden H, Louhab N, Kissani N. Medullary involvement in neurosyphilis: a report of 12 cases and a review of the literature. Spinal cord series and cases. 2019:5():38. doi: 10.1038/s41394-019-0185-9. Epub 2019 May 1     [PubMed PMID: 31632699]

Level 3 (low-level) evidence

[2]

Strom T, Schneck SA. Syphilitic meningomyelitis. Neurology. 1991 Feb:41(2 ( Pt 1)):325-6     [PubMed PMID: 1812840]


[3]

Ha T, Tadi P, Dubensky L. Neurosyphilis. StatPearls. 2024 Jan:():     [PubMed PMID: 31082023]


[4]

Rubin AN, Espiridion ED, Truong NH, Lofgren DH. Neurosyphilis Presenting with Anxiety: A Case Report. Cureus. 2018 Jul 22:10(7):e3020. doi: 10.7759/cureus.3020. Epub 2018 Jul 22     [PubMed PMID: 30254809]

Level 3 (low-level) evidence

[5]

Patton ME, Su JR, Nelson R, Weinstock H, Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis--United States, 2005-2013. MMWR. Morbidity and mortality weekly report. 2014 May 9:63(18):402-6     [PubMed PMID: 24807239]


[6]

Grey JA, Bernstein KT, Sullivan PS, Kidd SE, Gift TL, Hall EW, Hankin-Wei A, Weinstock HS, Rosenberg ES. Rates of Primary and Secondary Syphilis Among White and Black Non-Hispanic Men Who Have Sex With Men, United States, 2014. Journal of acquired immune deficiency syndromes (1999). 2017 Nov 1:76(3):e65-e73. doi: 10.1097/QAI.0000000000001508. Epub     [PubMed PMID: 28749823]


[7]

Wong W, Chaw JK, Kent CK, Klausner JD. Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003. Sexually transmitted diseases. 2005 Jul:32(7):458-63     [PubMed PMID: 15976605]


[8]

Landovitz RJ, Tseng CH, Weissman M, Haymer M, Mendenhall B, Rogers K, Veniegas R, Gorbach PM, Reback CJ, Shoptaw S. Epidemiology, sexual risk behavior, and HIV prevention practices of men who have sex with men using GRINDR in Los Angeles, California. Journal of urban health : bulletin of the New York Academy of Medicine. 2013 Aug:90(4):729-39. doi: 10.1007/s11524-012-9766-7. Epub     [PubMed PMID: 22983721]


[9]

Refugio ON, Klausner JD. Syphilis incidence in men who have sex with men with human immunodeficiency virus comorbidity and the importance of integrating sexually transmitted infection prevention into HIV care. Expert review of anti-infective therapy. 2018 Apr:16(4):321-331. doi: 10.1080/14787210.2018.1446828. Epub 2018 Mar 5     [PubMed PMID: 29489420]


[10]

Gonzalez H, Koralnik IJ, Marra CM. Neurosyphilis. Seminars in neurology. 2019 Aug:39(4):448-455. doi: 10.1055/s-0039-1688942. Epub 2019 Sep 18     [PubMed PMID: 31533185]


[11]

Hobbs E, Vera JH, Marks M, Barritt AW, Ridha BH, Lawrence D. Neurosyphilis in patients with HIV. Practical neurology. 2018 Jun:18(3):211-218. doi: 10.1136/practneurol-2017-001754. Epub 2018 Feb 24     [PubMed PMID: 29478035]


[12]

Tuddenham S, Ghanem KG. Neurosyphilis: Knowledge Gaps and Controversies. Sexually transmitted diseases. 2018 Mar:45(3):147-151. doi: 10.1097/OLQ.0000000000000723. Epub     [PubMed PMID: 29420441]


[13]

Purcell DW, Hall HI, Bernstein KL, Gift TL, McCray E, Mermin J. The Importance of Population Denominators for High-Impact Public Health for Marginalized Populations. JMIR public health and surveillance. 2016 May 17:2(1):e26. doi: 10.2196/publichealth.5883. Epub 2016 May 17     [PubMed PMID: 27244773]


[14]

Quintero-Moreno JF, Valencia-Vasquez A, Aguirre-Castaneda C. [Clinical and socio-demographic profile of neurosyphilis: a retrospective study in a reference centre in Colombia]. Revista de neurologia. 2019 Jul 16:69(2):53-58. doi: 10.33588/rn.6902.2018381. Epub     [PubMed PMID: 31287148]

Level 2 (mid-level) evidence

[15]

Tudor ME, Al Aboud AM, Leslie SW, Gossman W. Syphilis. StatPearls. 2024 Jan:():     [PubMed PMID: 30521201]


[16]

Fitzgerald TJ. Pathogenesis and immunology of Treponema pallidum. Annual review of microbiology. 1981:35():29-54     [PubMed PMID: 6457553]


[17]

Jolivet-Gougeon A, Bonnaure-Mallet M. Treponema, Iron and Neurodegeneration. Current Alzheimer research. 2018:15(8):716-722. doi: 10.2174/1567205013666161122093404. Epub     [PubMed PMID: 27875949]


[18]

Pandey S. Magnetic resonance imaging of the spinal cord in a man with tabes dorsalis. The journal of spinal cord medicine. 2011 Nov:34(6):609-11. doi: 10.1179/2045772311Y.0000000041. Epub     [PubMed PMID: 22330117]


[19]

Carmo RLD, Alves Simão AK, Amaral LLFD, Inada BSY, Silveira CF, Campos CMS, Freitas LF, Bonadio V, Marussi VHR. Neuroimaging of Emergent and Reemergent Infections. Radiographics : a review publication of the Radiological Society of North America, Inc. 2019 Oct:39(6):1649-1671. doi: 10.1148/rg.2019190020. Epub     [PubMed PMID: 31589575]


[20]

Corrêa DG, de Souza SR, Freddi TAL, Fonseca APA, Dos Santos RQ, Hygino da Cruz LC Jr. Imaging features of neurosyphilis. Journal of neuroradiology = Journal de neuroradiologie. 2023 Mar:50(2):241-252. doi: 10.1016/j.neurad.2023.01.003. Epub 2023 Jan 11     [PubMed PMID: 36641134]


[21]

Jum'ah A, Aboul Nour H, Alkhoujah M, Zoghoul S, Eltous L, Miller D. Neurosyphilis in disguise. Neuroradiology. 2022 Mar:64(3):433-441. doi: 10.1007/s00234-021-02827-3. Epub 2021 Oct 19     [PubMed PMID: 34665270]


[22]

Goh C, Desmond PM, Phal PM. MRI in transverse myelitis. Journal of magnetic resonance imaging : JMRI. 2014 Dec:40(6):1267-79. doi: 10.1002/jmri.24563. Epub 2014 Feb 6     [PubMed PMID: 24752988]


[23]

. Editorial: Hazards of tabes dorsalis. British medical journal. 1975 Dec 20:4(5998):669-70     [PubMed PMID: 1203718]

Level 3 (low-level) evidence

[24]

Huang YH, Shi QX, Xu MM, Chen CZ, Yang ML, Li JJ, Chen YF, Lin ZQ, Lin YY. Spinal Cord Syphilitic Gumma Presenting with Brown-Séquard Syndrome: A Case Report and Literature Review. Annals of clinical and laboratory science. 2019 Mar:49(2):265-270     [PubMed PMID: 31028074]


[25]

Koh PX, Neo SX, Chiew HJ, Singh DR, Saini M, Chen Z. Syphilitic Spinal Disease: An Old Nemesis Revisited. A Case Series and Review of Literature. Sexually transmitted diseases. 2021 Sep 1:48(9):e126-e131. doi: 10.1097/OLQ.0000000000001391. Epub     [PubMed PMID: 33512899]

Level 2 (mid-level) evidence

[26]

Centurion-Lara A, Castro C, Shaffer JM, Van Voorhis WC, Marra CM, Lukehart SA. Detection of Treponema pallidum by a sensitive reverse transcriptase PCR. Journal of clinical microbiology. 1997 Jun:35(6):1348-52     [PubMed PMID: 9163442]


[27]

Centurion-Lara A, Castro C, van Voorhis WC, Lukehart SA. Two 16S-23S ribosomal DNA intergenic regions in different Treponema pallidum subspecies contain tRNA genes. FEMS microbiology letters. 1996 Oct 1:143(2-3):235-40     [PubMed PMID: 8837477]

Level 3 (low-level) evidence

[28]

Ghanem KG, Ram S, Rice PA. The Modern Epidemic of Syphilis. The New England journal of medicine. 2020 Feb 27:382(9):845-854. doi: 10.1056/NEJMra1901593. Epub     [PubMed PMID: 32101666]


[29]

Davis AP, Stern J, Tantalo L, Sahi S, Holte S, Dunaway S, Marra CM. How Well Do Neurologic Symptoms Identify Individuals With Neurosyphilis? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Jan 18:66(3):363-367. doi: 10.1093/cid/cix799. Epub     [PubMed PMID: 29020214]


[30]

Sharma SR, Hussain M, Roy D. General paresis of insane: A forgotten entity. Neurology India. 2020 Mar-Apr:68(2):487-488. doi: 10.4103/0028-3886.284383. Epub     [PubMed PMID: 32415032]


[31]

Mukku S, Safal SS, Pritam R, Nashi S, Nagarathna C, Pt S, Netravathi M. Neurosyphilis presenting as rapidly progressive psychosis & dementia - A forgotten entity. Asian journal of psychiatry. 2019 Feb:40():103-106. doi: 10.1016/j.ajp.2019.02.010. Epub 2019 Feb 13     [PubMed PMID: 30785032]


[32]

Stefani A, Riello M, Rossini F, Mariotto S, Fenzi F, Gambina G, Zanusso G, Monaco S. Neurosyphilis manifesting with rapidly progressive dementia: report of three cases. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2013 Nov:34(11):2027-30. doi: 10.1007/s10072-013-1531-5. Epub 2013 Sep 6     [PubMed PMID: 24062212]

Level 3 (low-level) evidence

[33]

Yanhua W, Haishan S, Le H, Xiaomei Z, Xinru C, Ling L, Zhangying W, Dong Z, Yuefen Z, Yan T, Xinni L, Sha L, Yuping N. Clinical and neuropsychological characteristics of general paresis misdiagnosed as primary psychiatric disease. BMC psychiatry. 2016 Jul 11:16():230. doi: 10.1186/s12888-016-0925-3. Epub 2016 Jul 11     [PubMed PMID: 27400713]


[34]

Hamill MM, Ghanem KG, Tuddenham S. State-of-the-Art Review: Neurosyphilis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 Aug 18:():. pii: ciad437. doi: 10.1093/cid/ciad437. Epub 2023 Aug 18     [PubMed PMID: 37593890]


[35]

Dichter SL, Khan Suheb MZ, Shubert GS. Argyll Robertson Pupil. StatPearls. 2024 Jan:():     [PubMed PMID: 30725864]


[36]

Berger JR. Neurosyphilis and the spinal cord: then and now. The Journal of nervous and mental disease. 2011 Dec:199(12):912-3. doi: 10.1097/NMD.0b013e31823928e8. Epub     [PubMed PMID: 22134447]


[37]

Satishchandra P, Sinha S. Relevance of neuroimaging in the diagnosis and management of tropical neurologic disorders. Neuroimaging clinics of North America. 2011 Nov:21(4):737-56, vii. doi: 10.1016/j.nic.2011.07.002. Epub 2011 Sep 23     [PubMed PMID: 22032497]


[38]

Ledbetter LN, Salzman KL, Sanders RK, Shah LM. Spinal Neuroarthropathy: Pathophysiology, Clinical and Imaging Features, and Differential Diagnosis. Radiographics : a review publication of the Radiological Society of North America, Inc. 2016 May-Jun:36(3):783-99. doi: 10.1148/rg.2016150121. Epub 2016 Apr 8     [PubMed PMID: 27058729]


[39]

Urits I, Amgalan A, Israel J, Dugay C, Zhao A, Berger AA, Kassem H, Paladini A, Varrassi G, Kaye AD, Miriyala S, Viswanath O. A comprehensive review of the treatment and management of Charcot spine. Therapeutic advances in musculoskeletal disease. 2020:12():1759720X20979497. doi: 10.1177/1759720X20979497. Epub 2020 Dec 17     [PubMed PMID: 33414850]

Level 3 (low-level) evidence

[40]

Sobel JW, Bohlman HH, Freehafer AA. Charcot's arthropathy of the spine following spinal cord injury. A report of five cases. The Journal of bone and joint surgery. American volume. 1985 Jun:67(5):771-6     [PubMed PMID: 3997930]

Level 3 (low-level) evidence

[41]

Standaert C, Cardenas DD, Anderson P. Charcot spine as a late complication of traumatic spinal cord injury. Archives of physical medicine and rehabilitation. 1997 Feb:78(2):221-5     [PubMed PMID: 9041906]


[42]

Barrey C, Massourides H, Cotton F, Perrin G, Rode G. Charcot spine: two new case reports and a systematic review of 109 clinical cases from the literature. Annals of physical and rehabilitation medicine. 2010 Apr:53(3):200-20. doi: 10.1016/j.rehab.2009.11.008. Epub 2009 Dec 31     [PubMed PMID: 20338837]

Level 1 (high-level) evidence

[43]

Lee D, Dahdaleh NS. Charcot spinal arthropathy. Journal of craniovertebral junction & spine. 2018 Jan-Mar:9(1):9-19. doi: 10.4103/jcvjs.JCVJS_130_17. Epub     [PubMed PMID: 29755231]


[44]

Solinsky R, Donovan JM, Kirshblum SC. Charcot Spine following chronic spinal cord injury: an analysis of 201 published cases. Spinal cord. 2019 Feb:57(2):85-90. doi: 10.1038/s41393-018-0216-6. Epub 2018 Nov 9     [PubMed PMID: 30413802]

Level 3 (low-level) evidence

[45]

Morita M, Miyauchi A, Okuda S, Oda T, Yamamoto T, Iwasaki M. Charcot spinal disease after spinal cord injury. Journal of neurosurgery. Spine. 2008 Nov:9(5):419-26. doi: 10.3171/SPI.2008.9.11.419. Epub     [PubMed PMID: 18976172]


[46]

Hoyt D, Urits I, Orhurhu V, Orhurhu MS, Callan J, Powell J, Manchikanti L, Kaye AD, Kaye RJ, Viswanath O. Current Concepts in the Management of Vertebral Compression Fractures. Current pain and headache reports. 2020 Mar 20:24(5):16. doi: 10.1007/s11916-020-00849-9. Epub 2020 Mar 20     [PubMed PMID: 32198571]


[47]

Selmi F, Frankel HL, Kumaraguru AP, Apostopoulos V. Charcot joint of the spine, a cause of autonomic dysreflexia in spinal cord injured patients. Spinal cord. 2002 Sep:40(9):481-3     [PubMed PMID: 12185610]


[48]

Jacobs WB, Bransford RJ, Bellabarba C, Chapman JR. Surgical management of Charcot spinal arthropathy: a single-center retrospective series highlighting the evolution of management. Journal of neurosurgery. Spine. 2012 Nov:17(5):422-31. doi: 10.3171/2012.7.SPINE111039. Epub 2012 Aug 31     [PubMed PMID: 22938550]

Level 2 (mid-level) evidence

[49]

Dong H, Liu Z, Duan Y, Li D, Qiu Z, Liu Y, Huang J, Wang C. Syphilitic meningomyelitis misdiagnosed as spinal cord tumor: Case and review. The journal of spinal cord medicine. 2021 Sep:44(5):789-793. doi: 10.1080/10790268.2019.1658283. Epub 2019 Oct 11     [PubMed PMID: 31603731]

Level 2 (mid-level) evidence

[50]

Ghanem KG. REVIEW: Neurosyphilis: A historical perspective and review. CNS neuroscience & therapeutics. 2010 Oct:16(5):e157-68. doi: 10.1111/j.1755-5949.2010.00183.x. Epub 2010 Jul 8     [PubMed PMID: 20626434]

Level 3 (low-level) evidence

[51]

Mochizuki H, Kamakura K, Kanzaki M, Nishii T, Matsuo H, Motoyoshi K. Somatosensory evoked potential in neurosyphilis. Journal of neurology. 2002 Sep:249(9):1220-2     [PubMed PMID: 12242542]


[52]

Marra CM, Maxwell CL, Smith SL, Lukehart SA, Rompalo AM, Eaton M, Stoner BP, Augenbraun M, Barker DE, Corbett JJ, Zajackowski M, Raines C, Nerad J, Kee R, Barnett SH. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. The Journal of infectious diseases. 2004 Feb 1:189(3):369-76     [PubMed PMID: 14745693]


[53]

Hu R, Lu C, Lu S, Hu Y, Ma H, Lai W, Zhu G, Feng P, Lu R, Li Y. Value of CXCL13 in diagnosing asymptomatic neurosyphilis in HIV-infected patients. International journal of STD & AIDS. 2016 Feb:27(2):141-6. doi: 10.1177/0956462415577229. Epub 2015 Mar 12     [PubMed PMID: 25769888]


[54]

Marra CM. Neurosyphilis. Continuum (Minneapolis, Minn.). 2015 Dec:21(6 Neuroinfectious Disease):1714-28. doi: 10.1212/CON.0000000000000250. Epub     [PubMed PMID: 26633785]


[55]

Luger AF, Schmidt BL, Kaulich M. Significance of laboratory findings for the diagnosis of neurosyphilis. International journal of STD & AIDS. 2000 Apr:11(4):224-34     [PubMed PMID: 10772085]


[56]

Hooshmand H, Escobar MR, Kopf SW. Neurosyphilis. A study of 241 patients. JAMA. 1972 Feb:219(6):726-9     [PubMed PMID: 5066697]


[57]

Marra CM, Tantalo LC, Maxwell CL, Ho EL, Sahi SK, Jones T. The rapid plasma reagin test cannot replace the venereal disease research laboratory test for neurosyphilis diagnosis. Sexually transmitted diseases. 2012 Jun:39(6):453-7. doi: 10.1097/OLQ.0b013e31824b1cde. Epub     [PubMed PMID: 22592831]


[58]

Vanhaecke C, Grange P, Benhaddou N, Blanche P, Salmon D, Parize P, Lortholary O, Caumes E, Pelloux I, Epaulard O, Guinard J, Dupin N, Neurosyphilis Network, Neurosyphilis network. Clinical and Biological Characteristics of 40 Patients With Neurosyphilis and Evaluation of Treponema pallidum Nested Polymerase Chain Reaction in Cerebrospinal Fluid Samples. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Nov 1:63(9):1180-1186     [PubMed PMID: 27585981]


[59]

Ho EL, Marra CM. Treponemal tests for neurosyphilis--less accurate than what we thought? Sexually transmitted diseases. 2012 Apr:39(4):298-9. doi: 10.1097/OLQ.0b013e31824ee574. Epub     [PubMed PMID: 22421697]


[60]

Sun L, Zheng N, Yang Y, Zhang HN. Syphilitic meningomyelitis presenting with visceral crisis: A case report. Medicine. 2018 Jul:97(30):e11661. doi: 10.1097/MD.0000000000011661. Epub     [PubMed PMID: 30045319]

Level 3 (low-level) evidence

[61]

Yuan JL, Wang WX, Hu WL. Clinical features of syphilitic myelitis with longitudinally extensive myelopathy on spinal magnetic resonance imaging. World journal of clinical cases. 2019 Jun 6:7(11):1282-1290. doi: 10.12998/wjcc.v7.i11.1282. Epub     [PubMed PMID: 31236392]

Level 3 (low-level) evidence

[62]

Creech KT, Patel KM, Chaudhry U. Tabes Dorsalis in a Patient Presenting With Right Lower Extremity Paresthesia and Cervical Spine Pain. Cureus. 2021 Mar 20:13(3):e14011. doi: 10.7759/cureus.14011. Epub 2021 Mar 20     [PubMed PMID: 33884252]


[63]

Kikuchi S, Shinpo K, Niino M, Tashiro K. Subacute syphilitic meningomyelitis with characteristic spinal MRI findings. Journal of neurology. 2003 Jan:250(1):106-7     [PubMed PMID: 12528004]


[64]

Beers GJ, Carter AP, Leiter B, Shapiro JH. CT detection of retroperitoneal gas associated with gas in intervertebral disks. Journal of computer assisted tomography. 1984 Apr:8(2):232-6     [PubMed PMID: 6707271]


[65]

Sunagawa SW, Bergman SJ, Kreikemeier E, Watkins AB, Alexander BT, Miller MM, Schroeder D, Stohs EJ, Van Schooneveld TC, May SM. Use of a beta-lactam graded challenge process for inpatients with self-reported penicillin allergies at an academic medical center. Frontiers in allergy. 2023:4():1161683. doi: 10.3389/falgy.2023.1161683. Epub 2023 Jul 31     [PubMed PMID: 37588449]


[66]

Powell N, Stephens J, Kohl D, Owens R, Ahmed S, Musicha C, Upton M, Kent B, Tonkin-Crine S, Sandoe J. The effectiveness of interventions that support penicillin allergy assessment and delabeling of adult and pediatric patients by nonallergy specialists: a systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2023 Apr:129():152-161. doi: 10.1016/j.ijid.2022.11.026. Epub 2022 Nov 28     [PubMed PMID: 36450321]

Level 1 (high-level) evidence

[67]

Ramsey A, Staicu ML. Use of a Penicillin Allergy Screening Algorithm and Penicillin Skin Testing for Transitioning Hospitalized Patients to First-Line Antibiotic Therapy. The journal of allergy and clinical immunology. In practice. 2018 Jul-Aug:6(4):1349-1355. doi: 10.1016/j.jaip.2017.11.012. Epub 2017 Dec 11     [PubMed PMID: 29242142]


[68]

Ham Y, Sukerman ES, Lewis JS 2nd, Tucker KJ, Yu DL, Joshi SR. Safety and efficacy of direct two-step penicillin challenges with an inpatient pharmacist-driven allergy evaluation. Allergy and asthma proceedings. 2021 Mar 1:42(2):153-159. doi: 10.2500/aap.2021.42.200128. Epub     [PubMed PMID: 33685561]


[69]

Cao Y, Su X, Wang Q, Xue H, Zhu X, Zhang C, Jiang J, Qi S, Gong X, Zhu X, Pan M, Ren H, Hu W, Wei Z, Tian M, Liu W. A Multicenter Study Evaluating Ceftriaxone and Benzathine Penicillin G as Treatment Agents for Early Syphilis in Jiangsu, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Oct 30:65(10):1683-1688. doi: 10.1093/cid/cix611. Epub     [PubMed PMID: 29020150]

Level 2 (mid-level) evidence

[70]

Hook EW 3rd, Baker-Zander SA, Moskovitz BL, Lukehart SA, Handsfield HH. Ceftriaxone therapy for asymptomatic neurosyphilis. Case report and Western blot analysis of serum and cerebrospinal fluid IgG response to therapy. Sexually transmitted diseases. 1986 Jul-Sep:13(3 Suppl):185-8     [PubMed PMID: 3764632]

Level 3 (low-level) evidence

[71]

Ahmed KA, Fox SJ, Frigas E, Park MA. Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. International archives of allergy and immunology. 2012:158(4):405-10. doi: 10.1159/000333553. Epub 2012 Apr 5     [PubMed PMID: 22487723]

Level 2 (mid-level) evidence

[72]

Bettuzzi T, Jourdes A, Robineau O, Alcaraz I, Manda V, Molina JM, Mehlen M, Cazanave C, Tattevin P, Mensi S, Terrier B, Régent A, Ghosn J, Charlier C, Martin-Blondel G, Dupin N. Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study. The Lancet. Infectious diseases. 2021 Oct:21(10):1441-1447. doi: 10.1016/S1473-3099(20)30857-4. Epub 2021 May 26     [PubMed PMID: 34051142]

Level 2 (mid-level) evidence

[73]

Shuja SH, Naeem U, Eqbal F, Shuja MH. Ceftriaxone - A plausible intervention for treating neurosyphilis? Annals of medicine and surgery (2012). 2022 Oct:82():104662. doi: 10.1016/j.amsu.2022.104662. Epub 2022 Sep 15     [PubMed PMID: 36268347]


[74]

Novalbos A, Sastre J, Cuesta J, De Las Heras M, Lluch-Bernal M, Bombín C, Quirce S. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2001 Mar:31(3):438-43     [PubMed PMID: 11260156]


[75]

Dhakal A, Sbar E. Jarisch-Herxheimer Reaction. StatPearls. 2024 Jan:():     [PubMed PMID: 32491752]


[76]

Aebli N, Pötzel T, Krebs J. Characteristics and surgical management of neuropathic (Charcot) spinal arthropathy after spinal cord injury. The spine journal : official journal of the North American Spine Society. 2014 Jun 1:14(6):884-91. doi: 10.1016/j.spinee.2013.07.441. Epub 2013 Sep 26     [PubMed PMID: 24076443]


[77]

Suda Y, Shioda M, Kohno H, Machida M, Yamagishi M. Surgical treatment of Charcot spine. Journal of spinal disorders & techniques. 2007 Feb:20(1):85-8     [PubMed PMID: 17285059]


[78]

Cassidy RC, Shaffer WO. Charcot arthropathy because of congenital insensitivity to pain in an adult. The spine journal : official journal of the North American Spine Society. 2008 Jul-Aug:8(4):691-5     [PubMed PMID: 17602884]


[79]

Fiechter M, Bratelj D, Jaszczuk P, Capone C, Dragalina C, Pötzel T. Multi-rod fixation in spinal neuroarthropathy: a novel surgical technique. Journal of spine surgery (Hong Kong). 2023 Jun 30:9(2):176-185. doi: 10.21037/jss-22-103. Epub 2023 Mar 24     [PubMed PMID: 37435331]


[80]

Devlin VJ, Ogilvie JW, Transfeldt EE, Boachie-Adjei O, Bradford DS. Surgical treatment of neuropathic spinal arthropathy. Journal of spinal disorders. 1991 Sep:4(3):319-28     [PubMed PMID: 1802163]


[81]

Nielson DL, Armstrong DG. The natural history of Charcot's neuroarthropathy. Clinics in podiatric medicine and surgery. 2008 Jan:25(1):53-62, vi. doi: 10.1016/j.cpm.2007.10.004. Epub     [PubMed PMID: 18165111]


[82]

Pakarinen TK, Laine HJ, Mäenpää H, Kähönen M, Mattila P, Lahtela J. Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: a prospective randomized trial. Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons. 2013 Jun:19(2):121-4. doi: 10.1016/j.fas.2012.12.007. Epub 2013 Feb 20     [PubMed PMID: 23548455]

Level 1 (high-level) evidence

[83]

Pakarinen TK, Laine HJ, Mäenpää H, Mattila P, Lahtela J. The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial. Diabetes care. 2011 Jul:34(7):1514-6. doi: 10.2337/dc11-0396. Epub 2011 May 18     [PubMed PMID: 21593295]

Level 1 (high-level) evidence

[84]

Rastogi A, Bhansali A, Jude EB. Efficacy of medical treatment for Charcot neuroarthropathy: a systematic review and meta-analysis of randomized controlled trials. Acta diabetologica. 2021 Jun:58(6):687-696. doi: 10.1007/s00592-020-01664-9. Epub 2021 Jan 13     [PubMed PMID: 33439331]

Level 1 (high-level) evidence

[85]

Wang LL, Bierbrauer KS. Congenital and Hereditary Diseases of the Spinal Cord. Seminars in ultrasound, CT, and MR. 2017 Apr:38(2):105-125. doi: 10.1053/j.sult.2016.07.002. Epub 2016 Jul 14     [PubMed PMID: 28347415]


[86]

Wingerchuk DM. Immune-Mediated Myelopathies. Continuum (Minneapolis, Minn.). 2018 Apr:24(2, Spinal Cord Disorders):497-522. doi: 10.1212/CON.0000000000000582. Epub     [PubMed PMID: 29613897]


[87]

Schwendimann RN. Metabolic and Toxic Myelopathies. Continuum (Minneapolis, Minn.). 2018 Apr:24(2, Spinal Cord Disorders):427-440. doi: 10.1212/CON.0000000000000596. Epub     [PubMed PMID: 29613894]


[88]

Thurnher MM, Olatunji RB. Infections of the spine and spinal cord. Handbook of clinical neurology. 2016:136():717-31. doi: 10.1016/B978-0-444-53486-6.00035-1. Epub     [PubMed PMID: 27430438]


[89]

Chamberlain MC. Neoplastic myelopathies. Continuum (Minneapolis, Minn.). 2015 Feb:21(1 Spinal Cord Disorders):132-45. doi: 10.1212/01.CON.0000461089.02113.1b. Epub     [PubMed PMID: 25651222]


[90]

Vuong SM, Jeong WJ, Morales H, Abruzzo TA. Vascular Diseases of the Spinal Cord: Infarction, Hemorrhage, and Venous Congestive Myelopathy. Seminars in ultrasound, CT, and MR. 2016 Oct:37(5):466-81. doi: 10.1053/j.sult.2016.05.008. Epub 2016 May 6     [PubMed PMID: 27616317]